Novo Nordisk expects sales growth for 2026, which excludes revenue of $4.2 billion from the reversal of 340B provisions, is expected to be -5% to -13% at CER. The company said that the sales outlook ...
When facing a new sales year, your pipeline is often depleted. The focus on closing the previous year tends to shift activity away from creating new opportunities. As a result, opportunity creation ...
1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 44 of the Condensed Financial Report. Unless otherwise ...
With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies’ results and how they’re being received by investors. Today, we’re offering insight into the latest numbers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results